BEAM vs RGNX
BEAM: Beam Therapeutics is developing base editing medicines—a precision genetic cure approach—for serious inherited diseases like sickle cell disease and rare genetic disorders. RGNX: Clinical-stage gene therapy company using proprietary NAV vectors to deliver functional genes for rare genetic and retinal disorders through partnerships with major pharma.
Side-by-side fundamentals
| Metric | BEAM | RGNX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $26.64 | $10.20 | |
| Market cap as of 2026-07-23 | $2.7B | $529M | |
| PEG as of 2026-07-23 | n/a | -0.02 | |
| Net margin as of 2026-07-23 | -39.7% | -330.2% | BEAM higher |
| Gross margin as of 2026-07-23 | n/a | +68.2% | |
| Operating margin as of 2026-07-23 | -226.6% | -292.3% | BEAM higher |
| ROE as of 2026-07-23 | -5.9% | -232.5% | BEAM higher |
| ROA as of 2026-07-23 | -4.6% | -61.0% | BEAM higher |
| Debt / equity as of 2026-07-23 | 0.09 | 8.41 | BEAM lower |
| Revenue growth (YoY) as of 2026-07-23 | +158.0% | -44.0% | BEAM higher |
| Revenue CAGR (3y) SEC XBRL | +31.9% | +14.8% | BEAM higher |
| Beta as of 2026-07-23 | 2.22 | 0.91 | |
| 1-year return as of 2026-07-22 close | +29.8% | +19.0% | BEAM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.